INmune Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Equivalents	35.85	52.15	74.81	21.97	7	0.19	1.37	0.14
Cash & Cash Equivalents	35.85	52.15	74.81	21.97	7	0.19	1.37	0.14
Cash Growth	-31.26%	-30.29%	240.56%	214.02%	3656.91%	-86.42%	867.61%	-
Receivables	0	0	0	0	0	0.02	0.11	0.16
Other Current Assets	4.09	12.52	7.8	2.02	0.77	0.65	0.42	0.15
Total Current Assets	39.94	64.68	82.61	23.99	7.76	0.85	1.9	0.45
Property, Plant & Equipment	0.41	0.51	0.73	0.16	0.19	0	0	0
Goodwill and Intangibles	16.51	16.51	16.51	16.51	16.51	16.51	16.51	0
Other Long-Term Assets	0.13	0.1	0.1	0	0	0	0	0
Total Long-Term Assets	17.06	17.12	17.34	16.67	16.71	16.51	16.51	0
Total Assets	57	81.8	99.95	40.66	24.47	17.36	18.41	0.45
Accounts Payable	7.94	5.22	3.81	1.55	0.69	0.82	0.31	0.22
Current Debt	10.04	5.09	0.07	0.03	0.01	0	0	0.35
Other Current Liabilities	0.49	0.62	0.47	0.19	0	0	0	0.03
Total Current Liabilities	18.47	10.92	4.36	1.78	0.7	0.82	0.31	0.6
Long-Term Debt	0.4	10.22	15.16	0.13	0.16	0	0	0
Other Long-Term Liabilities	0	0.55	0.2	0	0	0	0	0
Total Long-Term Liabilities	0.4	10.77	15.36	0.13	0.16	0	0	0
Total Liabilities	18.86	21.69	19.72	1.9	0.86	0.82	0.31	0.6
Total Debt	10.44	15.31	15.23	0.16	0.17	0	0	0.35
Debt Growth	-31.83%	0.50%	9421.25%	-5.02%	-	-	-	-
Retained Earnings	-121.02	-91.01	-63.72	-33.38	-21.28	-13.6	-1.16	-0.33
Comprehensive Income	-0.8	-0.7	0	0.01	-0.01	0.01	0.03	-0
Shareholders' Equity	37.34	60.1	80.23	38.75	23.61	16.54	18.1	-0.15
Net Cash / Debt	25.41	36.84	59.58	21.81	6.83	0.19	1.37	-0.21
Net Cash / Debt Growth	-31.03%	-38.16%	173.20%	219.42%	3566.45%	-86.42%	-	-
Net Cash Per Share	1.41	2.06	3.69	1.82	0.66	0.02	0.21	-0.04
Working Capital	21.48	53.76	78.25	22.21	7.06	0.03	1.59	-0.15
Book Value Per Share	2.08	3.35	4.97	3.23	2.30	1.91	2.76	-0.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).